<div id="readability-page-1"><div><p><span>Fortress Biotech Inc </span><span>:</span></p><ul><li>FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDA</li><li>FORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES &amp; UP TO $129 MILLION IN MILESTONES</li></ul></div></div>

FBIO

<p>Fortress Biotech Inc :FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDAFORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES & UP TO $129 MILLION IN MILESTONES</p>

Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA